<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04903210</url>
  </required_header>
  <id_info>
    <org_study_id>NMNHTN-001</org_study_id>
    <nct_id>NCT04903210</nct_id>
  </id_info>
  <brief_title>Nicotinamide Mononucleotide in Hypertensive Patients</brief_title>
  <official_title>Pilot Study of Nicotinamide Mononucleotide Supplementation in Patients With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiovascular and cerebrovascular diseases are most terrible killers endangering the health&#xD;
      of Chinese residents, and hypertension is the most important risk factor. Hypertension&#xD;
      related vascular function and structural damage are the common pathological basis and&#xD;
      initiation of cardiovascular and cerebrovascular disease. Therefore, reducing blood pressure&#xD;
      and delaying or reversing vascular injury is an effective way to treat hypertension and&#xD;
      prevent cardiovascular disease. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme of&#xD;
      many kinds of dehydrogenases in the body, and is an essential molecule in the basic process&#xD;
      of life support. The latest research found that with the growth of age, the level of NAD+ is&#xD;
      decreasing, and increasing the content of NAD+ can prolong the life of multiple species&#xD;
      including human. NMN (β - nicotinamide mononucleotide) is a natural NAD+ precursor in cells.&#xD;
      Recent clinical trials found that NMN supplementation can effectively improve the level of&#xD;
      NAD+ in cells, delay aging, improve the metabolic process of cells without adverse reactions.&#xD;
      However, the effect of NMN supplementation on reducing blood pressure and protecting vascular&#xD;
      endothelial function has not been reported. Therefore, this study aims to focus on&#xD;
      hypertension, a major chronic disease, and to observe the effects of NMN supplementation on&#xD;
      vascular function and blood pressure in patients with hypertension, so as to provide a new&#xD;
      treatment strategy for hypertension and associated vascular injury.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 20, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Study biostatistician will be blinded to group (NMN vs. controls)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of NMN on flow mediated dilation (FMD)</measure>
    <time_frame>Up to 2 month</time_frame>
    <description>Change of FMD between NMN-treated participants and non-NMN-treated participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of NMN on brachial-ankle pulse wave velocity (baPWV)</measure>
    <time_frame>Up to 2 month</time_frame>
    <description>Change of baPWV between NMN-treated participants and non-NMN-treated participants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of NMN on blood pressure</measure>
    <time_frame>Up to 2 month</time_frame>
    <description>Change of systolic blood pressure and diastolic blood pressure between NMN-treated participants and non-NMN-treated participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of NMN on PBMC NAD+ levels</measure>
    <time_frame>Up to 2 month</time_frame>
    <description>Change of peripheral blood mononuclear cells NAD+ levels between NMN-treated participants and non-NMN-treated participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of NMN on sleep quality</measure>
    <time_frame>Up to 2 month</time_frame>
    <description>Change of the scores of Pittsburgh Sleep Quality Index (PSQI). The final score ranges from 0 to 21. The higher the score, the worse the sleep quality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment Adverse Events</measure>
    <time_frame>Up to 2 month</time_frame>
    <description>Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>NMN group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NMN10000 WRIGHT LIFE® + lifestyle modification.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Lifestyle modification only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nicotinamide mononucleotide supplied as 400mg capsule</intervention_name>
    <description>NMN10000 WRIGHT LIFE® + lifestyle modification NMN10000 WRIGHT LIFE®: 800mg, qd, for two months. Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.</description>
    <arm_group_label>NMN group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle modification</intervention_name>
    <description>Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>NMN group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Mild essential hypertensive patients (BP ranged from 140/90 to 159/99 mmHg).&#xD;
&#xD;
          -  Ability to undergo Study procedures.&#xD;
&#xD;
          -  Willingness/ability to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with secondary hypertension.&#xD;
&#xD;
          -  Participants suffering from diabetes mellitus, coronary heart disease, peripheral&#xD;
             vascular disease, acute or chronic liver disease, renal insufficiency, malignancies,&#xD;
             infectious disease, or using non-steroidal anti-inflammatory drugs, steriods,&#xD;
             vasoactive agents.&#xD;
&#xD;
          -  Known allergies to niacin or nicotinamide.&#xD;
&#xD;
          -  Receiving certain concurrent supplements.&#xD;
&#xD;
          -  Women who are currently pregnant or who wish to become pregnant over the course of the&#xD;
             study follow-up or who are at suckling period.&#xD;
&#xD;
          -  Unwillingness/inability to provide informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jun Tao</last_name>
    <phone>+86 13922191609</phone>
    <email>taojungz123@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yumin Qiu</last_name>
    <phone>+86 18022232920</phone>
    <email>qiuym8@mail2.sysu.edu.cn</email>
  </overall_contact_backup>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 21, 2021</study_first_submitted>
  <study_first_submitted_qc>May 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2021</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Jun Tao</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>β-nicotinamide mononucleotide</keyword>
  <keyword>Vascular function</keyword>
  <keyword>Blood pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

